About Novavax
Novavax (NASDAQ:NVAX) is a biotechnology firm focused on the development and commercialization of innovative vaccines to address serious infectious diseases. The company is particularly known for its work on vaccines for respiratory syncytial virus (RSV) and the coronavirus, with its NVX-CoV2373 vaccine candidate generating significant attention during the COVID-19 pandemic. Novavax aims to leverage its proprietary recombinant nanoparticle vaccine technology to create vaccine options that can improve global health outcomes. Its objectives include achieving regulatory approval for its vaccine candidates, increasing manufacturing capabilities, and forming strategic partnerships to ensure global distribution. By focusing on these goals, Novavax strives to meet the urgent need for effective vaccines, particularly in underserved populations around the world.
Snapshot
Operations
Produtos e/ou serviços de Novavax
- NVX-CoV2373, a protein-based COVID-19 vaccine authorized for emergency use in various countries.
- Influenza vaccine candidates, utilizing recombinant nanoparticle technology for seasonal flu protection.
- Combination respiratory vaccine targeting both COVID-19 and influenza in a single shot.
- NanoFlu, a quadrivalent influenza vaccine for older adults, showing positive Phase 3 clinical trial results.
- COVID-19 vaccine adaptations to address emerging variants and boosters.
- Collaboration on vaccine technology platforms for future infectious disease threats.
equipe executiva do Novavax
- Mr. John Charles Jacobs M.B.A.President, CEO & Director
- Mr. James Patrick Kelly C.F.A.Executive VP, CFO & Treasurer
- Mr. Mark J. Casey Esq.Executive VP, Chief Legal Officer & Corporate Secretary
- Ms. Elaine O'HaraExecutive VP & Chief Strategy Officer
- Mr. Richard P. CrowleyExecutive VP & COO
- Luis Sanay C.F.A.Vice President of Investor Relations
- Mr. Troy Morgan Esq., J.D.Senior VP, Deputy General Counsel & Chief Compliance Officer
- Ms. Erika S. TrahanAssociate Director of Investor & Public Relations
- Mr. Ian J. WatkinsExecutive VP & Chief Human Resources Officer
- Ms. Silvia Taylor M.B.A.Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden